Core Viewpoint - The article highlights a significant bullish trend in the A-share market, particularly in the innovative pharmaceutical sector, driven by favorable news regarding U.S. tariffs and strong market sentiment [1][10][12]. Market Performance - On May 29, major A-share indices rose, with the Shanghai Composite Index up 0.7% to 3363 points, the Shenzhen Component up 1.24%, and the ChiNext Index up 1.37%. Nearly 4500 stocks rose, with over a hundred hitting the daily limit [1]. - The financial technology, innovative pharmaceuticals, internet, and semiconductor sectors showed strong performance, with the innovative pharmaceutical sector experiencing the most significant gains [2][6]. Innovative Pharmaceutical Sector - The innovative pharmaceutical sector saw substantial price increases, with companies like Ruizhi Pharmaceutical, Shuyou Pharmaceutical, and Yifang Bio achieving 20% daily limits. Over ten other pharmaceutical stocks rose more than 10% [2][3]. - The Hang Seng Pharmaceutical ETF rose by 3.61%, with a year-to-date increase of 36.93%, while the newly launched Sci-Tech Pharmaceutical ETF gained 4% [5]. Tariff News Impact - A major positive development was the U.S. International Trade Court's decision to block the implementation of tariffs announced by Trump, which could significantly benefit Chinese pharmaceutical companies by alleviating concerns over high tariffs on medical supplies and APIs [10][11][15]. - The court's ruling is expected to create a more stable legal environment for Sino-U.S. pharmaceutical trade and technology cooperation, reducing potential risks for Chinese innovative drug companies [16]. Growth in License-out Transactions - There has been a notable increase in license-out transactions for Chinese pharmaceutical companies, with 94 deals totaling $51.9 billion completed in 2024, marking a 26% year-on-year growth. The first quarter of 2025 alone saw 41 transactions worth $36.9 billion [19]. - Major companies like Hengrui Medicine and Innovent Biologics have signed significant commercialization agreements, further boosting market confidence in the innovative pharmaceutical sector [20]. ASCO Conference and Clinical Trials - The upcoming ASCO conference is expected to showcase numerous innovative drug companies, with 71 original research results from Chinese firms selected for presentation, indicating the rapid rise of Chinese innovative drug enterprises [21][22]. - The oncology sector remains a focal point for innovation, with a significant portion of clinical trials and transactions centered around cancer treatments, reflecting the industry's growth potential [22]. Investment Opportunities - Despite recent strong performance, there are still numerous opportunities within the innovative pharmaceutical sector for long-term investment, particularly in companies with robust pipelines and significant market potential [24][25]. - The article suggests that investing in related ETFs, such as the Hang Seng Pharmaceutical ETF and the Sci-Tech Pharmaceutical ETF, may be a prudent strategy for those interested in the innovative pharmaceutical sector [27][30]. Market Sentiment and Fund Inflows - The innovative pharmaceutical sector has seen increased interest from institutional investors, with a 62% quarter-on-quarter increase in the total market value held by funds in the sector, reaching 57.6 trillion yuan [31][32].

暗盘资金正涌入这些股票，点击速看>>> 益方生物今日涨停，成交额4.36亿元，换手率3.94%，盘后龙虎榜数据显示，沪股通专用席位买入 1553.77万元并卖出1424.45万元，二机构专用席位净买入5875.50万元，二机构专用席位净卖出7150.95万 元。 ...

Market Overview - The A-share market saw a strong rise with the three major indices up, including the Shanghai Composite Index increasing by 0.7% to 3363.45 points, the Shenzhen Component rising by 1.24% to 10127.2 points, and the ChiNext Index up by 1.37% to 2012.55 points. The North Star 50 Index surged by 2.73% [1] - Total trading volume in the Shanghai, Shenzhen, and North exchanges reached 121.36 billion yuan, an increase of nearly 18 billion yuan compared to the previous day [1] Semiconductor Sector - The semiconductor sector experienced a significant rally, with stocks like GCL-Poly and Guangliwei both hitting the 20% limit up. Other notable performers included Huada Jiutian, which rose nearly 15%, and Taiji Co., which increased over 9% [5][6] - Reports indicated that the U.S. government is requesting local companies to stop exporting software related to semiconductor design technology to China, affecting major companies in the Electronic Design Automation (EDA) market [7] Innovative Drug Sector - The innovative drug concept saw a substantial increase, with stocks such as Ruizhi Pharmaceutical, Yifang Bio, and Shutaishen all hitting the 20% limit up. Changshan Pharmaceutical rose over 15%, reaching new highs [9][11] - Shutaishen announced that it received approval for clinical trials of its STSA-1002 injection for acute respiratory distress syndrome (ARDS), marking a significant step in its drug development [12] Data Element Sector - The data element concept showed strong performance, with stocks like Lakala, Xiongdi Technology, and Tianyang Technology all hitting the 20% limit up. Youbuxun rose over 14% [15][16] - The National Data Bureau announced the launch of the "Data Element ×" competition aimed at promoting the use of public and enterprise data, which is expected to enhance the economic and social development through better data application [17]

Group 1 - The Shanghai Stock Exchange Science and Technology Innovation Board Composite Index (000680) has seen a strong increase of 2.06%, with notable gains from component stocks such as GeLun Electronics (688206) up 20.01%, YiFang Bio (688382) up 20.00%, and JingJin Electric (688280) up 14.96% [3] - The Huaxia Science and Technology Innovation Index ETF (589000) rose by 1.97%, with a latest price of 0.93 yuan, and recorded a turnover rate of 3.41% during the trading session, with a transaction volume of 92.32 million yuan [3] - Over the past month, the average daily transaction volume of the Huaxia Science and Technology Innovation Index ETF reached 142 million yuan, ranking first among comparable funds [3] Group 2 - The recent China-Europe semiconductor upstream and downstream enterprise symposium emphasized the importance of leveraging complementary advantages and deepening trade cooperation while opposing unilateralism and bullying, aiming to maintain global semiconductor supply chain security and stability [3] - The Ministry of Commerce's emphasis on rare earth export control policies during the symposium may indicate a potential relaxation of export controls on rare earths for European chip companies [3] - Shanxi Securities noted that the tightening of chip export restrictions combined with the performance improvements of domestic chips will sustain high demand for AI computing power from downstream internet and intelligent computing centers [4] Group 3 - The focus is on first-tier manufacturers with significant performance improvements in new generation products on the chip side, and on the server side, the expected growth of H20 is anticipated to boost the performance of traditional server leaders [4] - The Huaxia Science and Technology Innovation Index ETF closely tracks the Shanghai Stock Exchange Science and Technology Innovation Board Composite Index, focusing on hard technology sectors, particularly in new generation information technology, high-end equipment, biomedicine, new energy, new materials, and energy conservation and environmental protection [4]

Group 1 - The A-share market saw a positive trend with the Shanghai Stock Exchange Science and Technology Innovation Board Biopharmaceutical Index rising by 1.95% as of the report time [1] - The Science and Technology Innovation Medicine Index ETF (588700) increased by 2.18%, with a turnover rate of 8.76% and a transaction volume exceeding 23.75 million [1] - Among the constituent stocks, Yifang Biotechnology-U surged over 12%, Borui Pharmaceutical rose over 8%, and Microchip Biotech increased over 7% [1] Group 2 - According to Industrial Securities, the innovative drug sector's prosperity is expected to be sustainable, with "innovation + internationalization" remaining the core direction of the pharmaceutical sector [2] - The report highlights that the innovative drug industry chain's fundamentals are beginning to improve, with overseas orders and performance starting to recover [2] - The demand in the domestic market is anticipated to rebound by 2025, with potential recovery in the consumption medical field, including medical services and OTC traditional Chinese medicine [2]

Investment Rating - The report maintains a positive investment outlook on URAT1 inhibitors, suggesting that they are expected to rapidly capture market opportunities in the coming years, particularly for domestic companies with strong clinical data and internationalization potential [4][6]. Core Insights - The gout and hyperuricemia patient population is substantial, with estimates of approximately 10.23 to 26.18 million gout patients and around 167 million hyperuricemia patients in China, indicating a significant unmet clinical need due to the side effects of existing medications [1][12][25]. - The global market for URAT1 inhibitors is competitive, with only one drug, Lesinurad, approved so far, which has shown superior efficacy in clinical trials compared to existing treatments [2][28]. - Domestic companies are advancing rapidly in the development of URAT1 inhibitors, with several products in late-stage clinical trials demonstrating promising efficacy and safety profiles [3][32]. Summary by Sections 1. Gout/Hyperuricemia and URAT1 Target Overview - The prevalence of gout and hyperuricemia is increasing, with a notable trend towards younger patients, and the current treatment options have significant side effects, highlighting a large unmet clinical demand [1][24][25]. - Existing medications for gout, such as allopurinol and febuxostat, have seen sales growth, but their side effects create a demand for safer and more effective alternatives [1][17][24]. 2. Domestic URAT1 Inhibitors Flourishing - URAT1 inhibitors work by inhibiting uric acid reabsorption, promoting uric acid excretion, and thus lowering serum uric acid levels [26]. - The first approved URAT1 inhibitor, Lesinurad, has shown a 74% success rate in clinical trials, significantly outperforming existing treatments [2][35]. - Several domestic companies, including HengRui Medicine and Yipinhong, are leading in the development of URAT1 inhibitors, with multiple candidates showing high efficacy rates in clinical trials [3][32][40]. 3. Investment Recommendations - The report recommends focusing on companies with strong clinical data and progress in the URAT1 inhibitor space, such as HengRui Medicine, Yipinhong, and Kangzhe Pharmaceutical, which are well-positioned for commercialization and international expansion [4][5].

中信证券股份有限公司 关于益方生物科技（上海）股份有限公司 2024 年度持续督导工作现场检查报告 根据《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等有 关法律、法规的规定，中信证券股份有限公司（以下简称"中信证券"或"保荐 人"）作为正在对益方生物科技（上海）股份有限公司（以下简称"益方生物" "公司""上市公司"）进行持续督导工作的保荐人，对 2024 年度（以下简称"本 持续督导期间"）的规范运作情况进行了现场检查，现就现场检查的有关情况报 告如下： 一、本次现场检查的基本情况 （一）保荐人 中信证券股份有限公司 （二）保荐代表人 杨沁、龚洁 （三）现场检查人员 杨沁、周增骏、黄中一 （四）现场检查时间 2025 年 4 月 11 日、2025 年 4 月 16 日至 18 日、2025 年 5 月 15 日 （五）现场检查内容 现场检查人员对本持续督导期内发行人公司治理和内部控制情况、信息披露 情况、公司的独立性以及与控股股东、实际控制人及其他关联方资金往来情况、 募集资金使用情况、关联交易、对外担保、重大对外投资情况、经营状况等方面 进行了现场检查，具体检查内容详见本报告"二、本次 ...

中信证券股份有限公司 关于益方生物科技（上海）股份有限公司 2024 年度持续督导跟踪报告 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为益方生 物科技（上海）股份有限公司（以下简称"益方生物"或"公司"或"上市公司"） 首次公开发行股票并在科创板上市的保荐人，根据《证券发行上市保荐业务管理 办法》《上海证券交易所科创板股票上市规则》等相关规定，中信证券履行持续 督导职责，并出具本持续督导年度跟踪报告。 一、持续督导工作概述 1、保荐人制定了持续督导工作制度，制定了相应的工作计划，明确了现场 检查的工作要求。 2、保荐人已与公司签订保荐协议，该协议已明确了双方在持续督导期间的 权利义务，并报上海证券交易所备案。 3、本持续督导期间，保荐人通过与公司的日常沟通、现场回访等方式开展 持续督导工作，并于 2025 年 4 月 11 日、2025 年 4 月 16 日至 18 日、2025 年 5 月 15 日对公司进行了现场检查。 4、本持续督导期间，保荐人根据相关法规和规范性文件的要求履行持续督 导职责，具体内容包括： （1）查阅公司章程、三会议事规则等公司治理制度、三会会议材料； （2）查阅公司财 ...

5月20日益方生物（688382）收盘价23.46元，收盘上涨15.62%，全天换手率5.34%，振幅13.17%，成交 额4.76亿元。科创板交易公开信息显示，当日该股因日收盘价涨幅达15%等上榜。 | 买入营业部名称 | 买入金额(万元) | | --- | --- | | 沪股通专用 | 4935.43 | | 机构专用 | 4244.64 | | 机构专用 | 3808.18 | | 机构专用 | 2198.97 | | 机构专用 | 1992.04 | | 卖出营业部名称 | 卖出金额(万元) | | 中国国际金融股份有限公司上海分公司 | 4549.00 | | 沪股通专用 | 4542.00 | | 兴业证券股份有限公司上海分公司 | 1600.85 | | 机构专用 | 1283.68 | | 机构专用 | 1222.04 | 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 （文章来源：证券时报网） 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交3.04亿元， 其中，买入成交额为1.72亿 元，卖出成交额为1.32亿元，合计净买入3981.70万元。具体来看，卖出营业部 ...

Market Overview - A-shares experienced a broad rally on May 20, with the Shanghai Composite Index closing up 0.38% at 3380.48 points, the Shenzhen Component up 0.77% at 10249.17 points, and the ChiNext Index up 0.77% at 2048.46 points. The total trading volume across the three exchanges reached 121.14 billion yuan, an increase of 9.23 billion yuan from the previous day [1][2]. Pet Economy - The pet economy concept saw significant gains, with Tianyuan Pet (301335) hitting a 20% limit up and reaching a new high. Lusi Co. (832419) also hit a limit up, marking a new high. Other companies in this sector, such as Bei Yin Mei (002570) and Yi Yi Co. (001206), also experienced limit up [4][5][6]. - Analysts noted that the pet market has maintained high growth rates in recent years, benefiting from domestic brand replacement effects and improvements in product and brand strength. This has led to significant year-on-year sales growth and price increases for domestic brands [7]. Innovative Drug Sector - The innovative drug sector showed strong performance, with Yipin Hong (300723) and San Sheng Guo Jian (688336) both hitting the 20% limit up. Other companies like Rongchang Bio (688331) and Yifang Bio (688382) saw increases of approximately 16% [8][9]. - San Sheng Guo Jian announced a collaboration with Pfizer for the exclusive global development and commercialization rights of a dual-target antibody, SSGJ-707, which has shown promising results in clinical trials for non-small cell lung cancer [10][11]. Shipping Sector - The shipping sector experienced a significant pullback, with companies like Guo Hang Yuan Yang (833171) dropping nearly 18%, and others such as Fenghuang Shipping (000520) and Lianyungang (601008) hitting their daily limit down [16][17]. - Lianyungang, which had seen five consecutive limit up days, reported a 48.01% year-on-year decline in net profit for the first quarter of 2025, raising concerns among investors [18][19].